로딩 중…
지수 로딩 중…
프로티아
303360· KOSDAQ· Health Care· Health Care Equipment & Services
₩4,100-1.20%
2026-06-19
Price Chart
프로티아+29.34%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 52.81B KRW |
| Revenue | 16.25B KRW |
| Net Income | 1.95B KRW |
| Total Assets | 34.13B KRW |
| Net Assets | 31.69B KRW |
| Employees | 89 |
| Value | |
| P/E | 27.14x |
| P/B | 1.67x |
| PEG | 0.73x |
| P/S | 3.25x |
| EV/EBITDA | 34.91x |
| FCF Yield | 5.69% |
| Profitability | |
| ROE | 6.14% |
| ROA | 5.70% |
| Op. Margin | 8.85% |
| Revenue Growth | 41.77% |
| Earnings Growth | 36.95% |
| Financial Health | |
| Debt Ratio | 107.72% |
| Total Debt | 0 KRW |
| FCF | 3.00B KRW |
| Cash | 2.58B KRW |
| Current Ratio | 10.74x |
| Net Debt/EBITDA | -1.80x |
| Performance | |
| 1Y Return | 29.34% |
| 1M Return | -10.09% |
| From 52W High | -40.49% |
| 1Y MDD | -40.92% |
| Trading | |
| Volume | 29,427 shares |
| Foreign Own. | 2.05% |
| Per Share | |
| EPS | 368 KRW |
| BPS | 2,460 KRW |
Company Info
Protia, established in 2000 and transferred its listing to the KOSDAQ Market in 2023, develops, manufactures, and sells medical devices based on core immunodiagnostic technology. The company produces and supplies human-use products with the world's highest number of simultaneous allergy diagnostic technologies, the first domestic pet products, and the first antibiotic susceptibility testing products utilizing a capacitance measurement method. Protia possesses development capabilities for 192-line allergy diagnostic products and pursues technological innovation by expanding into domestic and international markets. Protia is headquartered in Gangseo-gu, Seoul.